rs80359249
Variant summary
Our verdict is Uncertain significance. Variant got 1 ACMG points: 2P and 1B. PM2BP4
The NM_000059.4(BRCA2):c.9905G>A(p.Arg3302Lys) variant causes a missense change. The variant allele was found at a frequency of 0.00000248 in 1,614,040 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).
Frequency
Consequence
NM_000059.4 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Uncertain_significance. Variant got 1 ACMG points.
Transcripts
RefSeq
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
BRCA2 | ENST00000380152.8 | c.9905G>A | p.Arg3302Lys | missense_variant | Exon 27 of 27 | 5 | NM_000059.4 | ENSP00000369497.3 | ||
BRCA2 | ENST00000530893.7 | c.9536G>A | p.Arg3179Lys | missense_variant | Exon 27 of 27 | 1 | ENSP00000499438.2 | |||
BRCA2 | ENST00000614259.2 | n.*1963G>A | non_coding_transcript_exon_variant | Exon 26 of 26 | 2 | ENSP00000506251.1 | ||||
BRCA2 | ENST00000614259.2 | n.*1963G>A | 3_prime_UTR_variant | Exon 26 of 26 | 2 | ENSP00000506251.1 |
Frequencies
GnomAD3 genomes AF: 0.0000131 AC: 2AN: 152166Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.00000796 AC: 2AN: 251204Hom.: 0 AF XY: 0.00000737 AC XY: 1AN XY: 135758
GnomAD4 exome AF: 0.00000137 AC: 2AN: 1461874Hom.: 0 Cov.: 31 AF XY: 0.00000275 AC XY: 2AN XY: 727236
GnomAD4 genome AF: 0.0000131 AC: 2AN: 152166Hom.: 0 Cov.: 32 AF XY: 0.0000135 AC XY: 1AN XY: 74324
ClinVar
Submissions by phenotype
Breast-ovarian cancer, familial, susceptibility to, 2 Uncertain:3Benign:1
- -
- -
- -
This missense variant replaces arginine with lysine at codon 3302 of the BRCA2 protein. Computational prediction suggests that this variant may not impact protein structure and function (internally defined REVEL score threshold <= 0.5, PMID: 27666373). To our knowledge, functional studies have not been reported for this variant. This variant has been reported in at least four individuals affected with breast cancer and one unaffected individual (PMID: 12491499, 33471991; Leiden Open Variation Database DB-ID BRCA2_002114) and in an individual affected with adenocarcinoma (PMID: 28843361). A multifactorial analysis has reported tumor pathology, co-occurrence and family history likelihood ratios for pathogenicity of 1.77, 1.1022 and 0.1339, respectively (PMID: 31131967). This variant has been identified in 2/251204 chromosomes in the general population by the Genome Aggregation Database (gnomAD). The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance. -
not provided Uncertain:3
Variant summary: The BRCA2 c.9905G>A (p.Arg3302Lys) variant involves the alteration of a conserved nucleotide, resulting in a missense substitution and 4/5 in silico tools predict a damaging outcome for this variant. 5/5 splice prediction tools predict no significant impact on normal splicing but ESE finder predicts that this variant may introduce an SF2/ASF ESE site at the locus. However, functional studies have shown that the variant has not effect on splicing via RNA analysis from a patient blood sample (Houdayer_2012). This variant was found in the large control database ExAC at a frequency of 0.0000082 (1/121326 control chromosomes), which does not exceed the estimated maximal expected allele frequency of a pathogenic BRCA2 variant (0.0007503). In addition, multiple clinical diagnostic laboratories/reputable databases have classified this variant with differing interpretations, "uncertain significance" and "likely benign." Taken together, this variant is classified as a "Variant of Uncertain Significance (VUS)," until additional information becomes available (ie, clinical and functional studies). -
- -
In silico analysis, which includes protein predictors and evolutionary conservation, supports that this variant does not alter protein structure/function; Observed in at least one individual with breast cancer (Adem 2003); Also known as BRCA2 10133G>A; This variant is associated with the following publications: (PMID: 12491499, 22505045) -
Hereditary cancer-predisposing syndrome Uncertain:2
The p.R3302K variant (also known as c.9905G>A), located in coding exon 26 of the BRCA2 gene, results from a G to A substitution at nucleotide position 9905. The arginine at codon 3302 is replaced by lysine, an amino acid with highly similar properties. This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. -
This missense variant replaces arginine with lysine at codon 3302 of the BRCA2 protein. Computational prediction suggests that this variant may not impact protein structure and function (internally defined REVEL score threshold <= 0.5, PMID: 27666373). To our knowledge, functional studies have not been reported for this variant. This variant has been reported in at least four individuals affected with breast cancer and one unaffected individual (PMID: 12491499, 33471991; Leiden Open Variation Database DB-ID BRCA2_002114) and in an individual affected with adenocarcinoma (PMID: 28843361). A multifactorial analysis has reported tumor pathology, co-occurrence and family history likelihood ratios for pathogenicity of 1.77, 1.1022 and 0.1339, respectively (PMID: 31131967). This variant has been identified in 2/251204 chromosomes in the general population by the Genome Aggregation Database (gnomAD). The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance. -
not specified Uncertain:1
- -
BRCA2-related disorder Uncertain:1
The BRCA2 c.9905G>A variant is predicted to result in the amino acid substitution p.Arg3302Lys. This variant has been reported in an individual with breast cancer (Table 1, Adem et al. 2003. PubMed ID: 12491499). This variant is reported in 0.0062% of alleles in individuals of African descent in gnomAD (http://gnomad.broadinstitute.org/variant/13-32972555-G-A) and is interpreted as uncertain significance by the vast majority of submitters in ClinVar (https://preview.ncbi.nlm.nih.gov/clinvar/variation/52913/). At this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. -
Hereditary breast ovarian cancer syndrome Benign:1
- -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at